苏州药明巨诺生物科技有限公司

WuXi ATU (HKEX: 2126) is an independent biotechnology company dedicated to the development, manufacturing, and commercialization of cell immunotherapy products. Established in 2016, WuXi ATU is committed to becoming a leader in cell immunotherapy through innovation. The company has developed a leading global platform for technology and product development in cell immunotherapy and a promising pipeline covering both hematological cancers and solid tumors, aiming to bring the hope of a cure to Chinese and global patients while promoting the healthy and standardized development of China's cell immunotherapy industry.